Oncoteq
Clinical-stage biotech leveraging AI for oncology drug development.
Website: https://www.oncoteq.ch/
Cover Block
| Field | Value |
|---|---|
| Name | Oncoteq AG |
| Tagline | Clinical-stage biotech leveraging AI for oncology drug development |
| Headquarters | Cham, Switzerland |
| Founded | 2022 |
| Stage | Seed |
| Business Model | B2B |
| Industry | Healthtech / Oncology |
| Technology Type | Biotech / Life Sciences (AI-supported drug development) |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Funding Label | Seed (lead: Cureteq) |
Links
- Website: https://www.oncoteq.ch/
- LinkedIn (parent / company-builder): https://ch.linkedin.com/company/cureteq
- Swiss commercial registry profile: https://www.moneyhouse.ch/en/company/oncoteq-ag-20514838621
Executive Summary
Oncoteq AG is a Cham-based clinical-stage oncology biotech assembled inside the Cureteq company-builder platform, with a thesis that AI-supported asset selection plus disciplined in-licensing can compress the cost and timeline of early oncology development [Oncoteq] [Cureteq]. The company was founded and seeded by Cureteq, a Partex group entity [Cureteq]. Its current pipeline comprises three named assets, TEQ101, TEQ102 and TEQ103, with the latter two acquired through in-licensing transactions disclosed in late 2023 [Oncoteq, Nov 2023]. TEQ102, formerly TUB-010, is an anti-CD30 antibody-drug conjugate in-licensed from Tubulis GmbH for T-cell and Hodgkin's lymphoma indications [ADC Review] [IZB]. TEQ103 is a worldwide-exclusive license targeting estrogen receptor alpha positive breast cancer through a stress-response mechanism [Oncoteq, Nov 2023] [IGB Illinois]. Leadership is anchored by CEO Mads Dalsgaard, CBO Sarah Holland, and CFO Swati Mehta [Cureteq, Jan 2024].
Data Accuracy: GREEN -- Confirmed across the Oncoteq corporate site, Cureteq portfolio page, and Swiss Moneyhouse registry.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed, clinical-stage assets |
| Business Model | B2B (drug developer; out-licensing / partnering optionality) |
| Industry / Vertical | Oncology therapeutics |
| Technology Type | Antibody-drug conjugates and small molecules, AI-supported asset selection |
| Geography | Switzerland (Cham, Canton of Zug) |
| Growth Profile | Venture scale, capital-intensive |
| Funding | Seed, lead Cureteq |
How the Company Got Here
Oncoteq is a clinical-stage oncology biotech founded in 2022 and headquartered at Maschinengasse 10, 6330 Cham, in the Swiss Canton of Zug, registered as Oncoteq AG under Swiss commercial identifier CHE-234.928.941 [Oncoteq] [Moneyhouse]. The company leverages AI to unlock the value of oncology assets within the Cureteq platform [Oncoteq] [Cureteq]. Cureteq is part of the Partex group, and Oncoteq is the entity responsible for the development of TEQ101, TEQ102 and TEQ103 [Cureteq].
Following formation in 2022, Oncoteq announced two in-licensing transactions in November 2023: an agreement with Munich-based Tubulis GmbH bringing in TUB-010 (renamed TEQ102), an IND-ready anti-CD30 antibody-drug conjugate, and a separate worldwide-exclusive license for TEQ103, a breast cancer compound originating from academic work associated with the Institute for Genomic Biology in Illinois [Oncoteq, Nov 2023] [IZB] [IGB Illinois]. In August 2024 the company sponsored Tiffany's Pink Pedal Ride for breast cancer research [Oncoteq].
Data Accuracy: GREEN -- Corroborated by the Oncoteq corporate site, Cureteq portfolio page, and the Moneyhouse Swiss registry entry.
Product and Technology
Oncoteq's pipeline currently presents three assets. TEQ101 is named on the corporate pipeline page but its mechanism and indication are not disclosed [Oncoteq]. TEQ102 is an anti-CD30 antibody-drug conjugate in-licensed from Tubulis GmbH, formerly designated TUB-010, positioned for the treatment of T-cell lymphoma and Hodgkin's lymphoma [Oncoteq, Nov 2023] [ADC Review] [IZB]. The asset was reported as IND-ready at the time of out-licensing [IZB].
TEQ103 is a small-molecule compound targeting estrogen receptor alpha (ERα) positive breast cancer cells and selectively killing cells with an activated unfolded protein response (a-UPR) [Oncoteq, Nov 2023] [IGB Illinois]. Oncoteq holds a worldwide exclusive license for TEQ103 [Oncoteq, Nov 2023]. The Cureteq platform language refers to AI-supported drug development combined with a company-builder model [Cureteq].
Data Accuracy: YELLOW -- Pipeline assets and mechanisms are corroborated across Oncoteq, Tubulis-related, and IGB Illinois sources; the AI methodology is described only in marketing language.
Market Research and Opportunity
Oncology drug development remains the largest therapeutic spending category. The company's framing for TEQ103 references a global breast cancer treatment market of approximately USD 25 to 30 billion annually [Oncoteq, Nov 2023]. For TEQ102, the addressable patient populations are smaller in absolute count: classical Hodgkin lymphoma and CD30-expressing T-cell lymphomas have established ADC precedent through brentuximab vedotin (Adcetris).
| Sizing claim | Value |
|---|---|
| Global breast cancer treatments, annual | ~USD 25-30 billion |
Data Accuracy: YELLOW -- The single sizing figure is company-sourced and directional; surrounding market context is drawn from established public knowledge.
Competitive Landscape
Oncoteq competes in the anti-CD30 ADC space for hematologic malignancy via TEQ102, and ER+ breast cancer via TEQ103. In the CD30-ADC segment, the incumbent is brentuximab vedotin (Adcetris), commercialized by Pfizer and Takeda. The differentiated angle for TEQ102 is the Tubulis P5 conjugation chemistry designed to improve the therapeutic index of ADCs [IZB].
In ER+ breast cancer, the competitive set includes CDK4/6 inhibitors (Ibrance, Kisqali, Verzenio) and oral SERDs (elacestrant). TEQ103's a-UPR-targeting mechanism is distinct, but it enters a market where prescribers have many shots on goal [Oncoteq, Nov 2023] [IGB Illinois].
Data Accuracy: YELLOW -- Subject-company facts are GREEN-cited; competitor framing draws on established public knowledge.
Opportunity
The headline opportunity is to become a focused clinical-development house that converts two in-licensed assets into partnered or out-licensed programs at IND or Phase Ib inflection points, with TEQ103 as the lead value driver in a roughly USD 25 to 30 billion global breast cancer treatment market [Oncoteq, Nov 2023].
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Partnered ADC | TEQ102 reaches clinic and attracts a strategic partner | Positive Phase I dose-escalation | Adcetris precedent and Tubulis P5 chemistry pedigree [IZB] |
| ER+ breakout | TEQ103 generates clean monotherapy signal | First-in-human readout | Mechanism is orthogonal to the dominant SERD/CDK4/6 axis [IGB Illinois] [Oncoteq, Nov 2023] |
| Platform compounding | Cureteq adds further in-licensed assets | Additional in-licensing announcements | Builder model is designed for serial asset acquisition [Cureteq] |
Data Accuracy: YELLOW -- Pipeline and licensing facts are GREEN-cited; comparable transaction values are widely reported public knowledge.
Sources
- [Oncoteq] Oncoteq corporate site | https://www.oncoteq.ch/
- [Oncoteq] About Us, Oncoteq | https://www.oncoteq.ch/about-us/
- [Oncoteq] Pipeline, Oncoteq | https://www.oncoteq.ch/pipeline/
- [Oncoteq] Platform, Oncoteq | https://www.oncoteq.ch/platform/
- [Oncoteq] Investors and Media, Oncoteq | https://www.oncoteq.ch/investors-media/
- [Oncoteq] Team, Oncoteq | https://www.oncoteq.ch/about-us/team/
- [Oncoteq] Contact, Oncoteq | https://www.oncoteq.ch/contact/
- [Oncoteq, Nov 2023] Oncoteq expands pipeline with TEQ103 | https://www.oncoteq.ch/2023/11/oncoteq-expands-pipeline-with-teq103-a-promising-treatment-for-breast-cancer/
- [Oncoteq, Nov 2023] Press release: Oncoteq completes another in-licensing deal | https://www.oncoteq.ch/2023/11/oncoteq-completes-another-in-licensing-deal-adding-a-potential-best-in-class-cd30-antibody-drug-conjugate-from-tubulis-to-its-oncology-pipeline/
- [Cureteq] Oncoteq portfolio page, Cureteq | https://www.cureteq.com/portfolio/oncoteq/
- [Cureteq] Portfolio, Cureteq | https://www.cureteq.com/portfolio/
- [Cureteq, Jan 2024] Meeting at J.P. Morgan 2024, Cureteq | https://www.cureteq.com/2024/01/meeting-at-j-p-morgan-2024/
- [IZB] Tubulis out-licenses IND-ready ADC | https://www.izb-online.de/en/izb-biotech-news/tubulis-out-licenses-ind-ready-adc-for-the-treatment-of-lymphoma-to-oncoteq-innovations-und-gruenderzentrum-biotechnologie-izb/
- [Crunchbase] Cureteq AG, Crunchbase profile | https://www.crunchbase.com/organization/cureteq-ag
- [Moneyhouse] Oncoteq AG in Cham, Moneyhouse company report | https://www.moneyhouse.ch/en/company/oncoteq-ag-20514838621
- [LinkedIn] Cureteq AG, a Partex Company, LinkedIn page | https://ch.linkedin.com/company/cureteq
Articles about Oncoteq
- Oncoteq Is Betting Three In-Licensed Oncology Assets on an AI-Assisted Build — The Cham, Switzerland biotech, seeded by Cureteq, is chasing breast cancer and lymphoma patients with a company-builder model.